Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis

    September 2015 in “ Clinical Therapeutics
    Aaron Miller
    TLDR Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
    Teriflunomide was an FDA-approved oral medication for relapsing multiple sclerosis, demonstrating significant efficacy in reducing relapse rates and disease progression in clinical trials. The 14-mg dose notably reduced the annualized relapse rate by up to 36% and decreased disability progression risk, while the 7-mg dose was less effective in preventing disability progression. MRI results supported its efficacy by showing reduced lesion volume. Common adverse events included headache, increased liver enzymes, diarrhea, and alopecia. Due to potential teratogenic effects, it was contraindicated in pregnancy, and routine monitoring was recommended. Overall, teriflunomide was considered an effective treatment option with a favorable benefit-risk profile.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 26 results